Simulations Plus (NASDAQ:SLP) Issues FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.07-$1.20 for the period, compared to the consensus earnings per share estimate of $1.01. The company issued revenue guidance of $90-$93 million, compared to the consensus revenue estimate of $90.71 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Up 4.4 %

Simulations Plus stock traded up $1.29 during trading hours on Tuesday, hitting $30.39. The stock had a trading volume of 492,972 shares, compared to its average volume of 303,448. The stock’s 50-day moving average price is $29.78 and its 200-day moving average price is $34.16. The stock has a market capitalization of $610.38 million, a P/E ratio of 62.02 and a beta of 0.80. Simulations Plus has a 12-month low of $27.07 and a 12-month high of $51.22.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $19.73 million. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm’s quarterly revenue was up 19.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.18 EPS. On average, research analysts expect that Simulations Plus will post 1.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SLP shares. BTIG Research dropped their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Stephens initiated coverage on shares of Simulations Plus in a report on Friday, November 15th. They set an “overweight” rating and a $39.00 target price for the company. Finally, William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Insider Activity

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the sale, the director now directly owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. The trade was a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 19.40% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.